
    
      The purpose of this single arm, open label study is to determine whether iptacopan is
      efficacious and safe for the treatment of PNH patients who are naive to complement inhibitor
      therapy, including anti-C5 antibody.

      The study is planned to have approximately 40 PNH patients starting study treatment in
      various countries.
    
  